Skip to main content
NCBI home page
Molecular Pathology : MP logoLink to Molecular Pathology : MP
. 1998 Dec;51(6):293–304. doi: 10.1136/mp.51.6.293

Genetic risk factors in Alzheimer's disease.

L Tilley 1, K Morgan 1, N Kalsheker 1
PMCID: PMC395655  PMID: 10193509

Abstract

Following a brief introduction and discussion of the pathological features of Alzheimer's disease, the main emphasis of this review article will be the genetic factors that have been implicated in this disease. These can be divided into two main categories. First, the three genes in which mutations are known to result in early onset autosomal dominant familial Alzheimer's disease will be discussed. These are well characterised but account for only a small proportion of Alzheimer's disease cases. Late onset, sporadic Alzheimer's disease is more common and evidence suggests that there is a genetic component to this type of disease. A number of genetic risk factors have been implicated that might increase the risk of developing sporadic disease. Many of these are controversial and studies have shown conflicting results, which are discussed in this section. Finally, a brief discussion of some of the mechanisms suggested to play a role in the pathogenesis of Alzheimer's disease is included. It is hoped that this will show why particular genes have been implicated in Alzheimer's disease and how they might be able to influence the development of the disease.

Full Text

The Full Text of this article is available as a PDF (280.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham C. R., Selkoe D. J., Potter H. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell. 1988 Feb 26;52(4):487–501. doi: 10.1016/0092-8674(88)90462-x. [DOI] [PubMed] [Google Scholar]
  2. Aksenov M. Y., Aksenova M. V., Carney J. M., Butterfield D. A. Alpha 1-antichymotrypsin interaction with A beta (1-42) does not inhibit fibril formation but attenuates the peptide toxicity. Neurosci Lett. 1996 Oct 18;217(2-3):117–120. [PubMed] [Google Scholar]
  3. Arinami T., Takekoshi K., Yanagi H., Hamamoto M., Hamaguchi H. The 5-repeat allele in the very-low-density lipoprotein receptor gene polymorphism is not increased in sporadic Alzheimer's disease in Japanese. Neurology. 1996 Nov;47(5):1349–1350. doi: 10.1212/wnl.47.5.1349. [DOI] [PubMed] [Google Scholar]
  4. Bartels C. F., Jensen F. S., Lockridge O., van der Spek A. F., Rubinstein H. M., Lubrano T., La Du B. N. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet. 1992 May;50(5):1086–1103. [PMC free article] [PubMed] [Google Scholar]
  5. Baudier J., Cole R. D. Phosphorylation of tau proteins to a state like that in Alzheimer's brain is catalyzed by a calcium/calmodulin-dependent kinase and modulated by phospholipids. J Biol Chem. 1987 Dec 25;262(36):17577–17583. [PubMed] [Google Scholar]
  6. Behl C., Davis J. B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 1994 Jun 17;77(6):817–827. doi: 10.1016/0092-8674(94)90131-7. [DOI] [PubMed] [Google Scholar]
  7. Bickeböller H., Campion D., Brice A., Amouyel P., Hannequin D., Didierjean O., Penet C., Martin C., Pérez-Tur J., Michon A. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet. 1997 Feb;60(2):439–446. [PMC free article] [PubMed] [Google Scholar]
  8. Blacker D., Wilcox M. A., Laird N. M., Rodes L., Horvath S. M., Go R. C., Perry R., Watson B., Jr, Bassett S. S., McInnis M. G. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet. 1998 Aug;19(4):357–360. doi: 10.1038/1243. [DOI] [PubMed] [Google Scholar]
  9. Bowen D. M., Smith C. B., White P., Davison A. N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 1976 Sep;99(3):459–496. doi: 10.1093/brain/99.3.459. [DOI] [PubMed] [Google Scholar]
  10. Braak H., Braak E., Bohl J., Reintjes R. Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease. Neurosci Lett. 1996 May 31;210(2):87–90. doi: 10.1016/0304-3940(96)12668-9. [DOI] [PubMed] [Google Scholar]
  11. Brindle N., Song Y., Rogaeva E., Premkumar S., Levesque G., Yu G., Ikeda M., Nishimura M., Paterson A., Sorbi S. Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease. Hum Mol Genet. 1998 May;7(5):933–935. doi: 10.1093/hmg/7.5.933. [DOI] [PubMed] [Google Scholar]
  12. Bullido M. J., Artiga M. J., Recuero M., Sastre I., García M. A., Aldudo J., Lendon C., Han S. W., Morris J. C., Frank A. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet. 1998 Jan;18(1):69–71. doi: 10.1038/ng0198-69. [DOI] [PubMed] [Google Scholar]
  13. Campion D., Brice A., Dumanchin C., Puel M., Baulac M., De La Sayette V., Hannequin D., Duyckaerts C., Michon A., Martin C. A novel presenilin 1 mutation resulting in familial Alzheimer's disease with an onset age of 29 years. Neuroreport. 1996 Jul 8;7(10):1582–1584. doi: 10.1097/00001756-199607080-00009. [DOI] [PubMed] [Google Scholar]
  14. Carson K. A., Geula C., Mesulam M. M. Electron microscopic localization of cholinesterase activity in Alzheimer brain tissue. Brain Res. 1991 Feb 1;540(1-2):204–208. doi: 10.1016/0006-8993(91)90508-s. [DOI] [PubMed] [Google Scholar]
  15. Chartier-Harlin M. C., Crawford F., Houlden H., Warren A., Hughes D., Fidani L., Goate A., Rossor M., Roques P., Hardy J. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature. 1991 Oct 31;353(6347):844–846. doi: 10.1038/353844a0. [DOI] [PubMed] [Google Scholar]
  16. Chartier-Harlin M. C., Parfitt M., Legrain S., Pérez-Tur J., Brousseau T., Evans A., Berr C., Vidal O., Roques P., Gourlet V. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet. 1994 Apr;3(4):569–574. doi: 10.1093/hmg/3.4.569. [DOI] [PubMed] [Google Scholar]
  17. Chung H., Roberts C. T., Greenberg S., Rebeck G. W., Christie R., Wallace R., Jacob H. J., Hyman B. T. Lack of association of trinucleotide repeat polymorphisms in very-low-density lipoprotein receptor gene with Alzheimer's disease. Ann Neurol. 1996 Jun;39(6):800–803. doi: 10.1002/ana.410390617. [DOI] [PubMed] [Google Scholar]
  18. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med. 1997 Jan;3(1):67–72. doi: 10.1038/nm0197-67. [DOI] [PubMed] [Google Scholar]
  19. Clatworthy A. E., Gomez-Isla T., Rebeck G. W., Wallace R. B., Hyman B. T. Lack of association of a polymorphism in the low-density lipoprotein receptor-related protein gene with Alzheimer disease. Arch Neurol. 1997 Oct;54(10):1289–1292. doi: 10.1001/archneur.1997.00550220087019. [DOI] [PubMed] [Google Scholar]
  20. Corder E. H., Saunders A. M., Risch N. J., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Jr, Rimmler J. B., Locke P. A., Conneally P. M., Schmader K. E. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994 Jun;7(2):180–184. doi: 10.1038/ng0694-180. [DOI] [PubMed] [Google Scholar]
  21. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Jr, Roses A. D., Pericak-Vance M. A., Small G. W., Haines J. L. The apolipoprotein E E4 allele and sex-specific risk of Alzheimer's disease. JAMA. 1995 Feb 1;273(5):373–374. [PubMed] [Google Scholar]
  22. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993 Aug 13;261(5123):921–923. doi: 10.1126/science.8346443. [DOI] [PubMed] [Google Scholar]
  23. Davies P., Maloney A. J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976 Dec 25;2(8000):1403–1403. doi: 10.1016/s0140-6736(76)91936-x. [DOI] [PubMed] [Google Scholar]
  24. Davis R. E., Miller S., Herrnstadt C., Ghosh S. S., Fahy E., Shinobu L. A., Galasko D., Thal L. J., Beal M. F., Howell N. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4526–4531. doi: 10.1073/pnas.94.9.4526. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  25. Didierjean O., Martinez M., Campion D., Hannequin D., Dubois B., Martin C., Puel M., Thomas Anterion C., Pasquier F., Moreau O. No effect of the alpha1-antichymotrypsin A allele in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):103–105. doi: 10.1136/jnnp.63.1.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Dragunow M., Faull R. L., Lawlor P., Beilharz E. J., Singleton K., Walker E. B., Mee E. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport. 1995 May 9;6(7):1053–1057. doi: 10.1097/00001756-199505090-00026. [DOI] [PubMed] [Google Scholar]
  27. Drechsel D. N., Hyman A. A., Cobb M. H., Kirschner M. W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell. 1992 Oct;3(10):1141–1154. doi: 10.1091/mbc.3.10.1141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Du Y., Bales K. R., Dodel R. C., Liu X., Glinn M. A., Horn J. W., Little S. P., Paul S. M. Alpha2-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. J Neurochem. 1998 Mar;70(3):1182–1188. doi: 10.1046/j.1471-4159.1998.70031182.x. [DOI] [PubMed] [Google Scholar]
  29. Du Y., Ni B., Glinn M., Dodel R. C., Bales K. R., Zhang Z., Hyslop P. A., Paul S. M. alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein. J Neurochem. 1997 Jul;69(1):299–305. [PubMed] [Google Scholar]
  30. Duff K., Eckman C., Zehr C., Yu X., Prada C. M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996 Oct 24;383(6602):710–713. doi: 10.1038/383710a0. [DOI] [PubMed] [Google Scholar]
  31. Edland S. D., Silverman J. M., Peskind E. R., Tsuang D., Wijsman E., Morris J. C. Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology. 1996 Jul;47(1):254–256. doi: 10.1212/wnl.47.1.254. [DOI] [PubMed] [Google Scholar]
  32. Eikelenboom P., Hack C. E., Kamphorst W., Rozemuller J. M. Distribution pattern and functional state of complement proteins and alpha 1-antichymotrypsin in cerebral beta/A4 deposits in Alzheimer's disease. Res Immunol. 1992 Jul-Aug;143(6):617–620. doi: 10.1016/0923-2494(92)80044-l. [DOI] [PubMed] [Google Scholar]
  33. Fallin D., Gauntlett A. C., Scibelli P., Cai X., Duara R., Gold M., Crawford F., Mullan M. No association between the very low density lipoprotein receptor gene and late-onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. Genet Epidemiol. 1997;14(3):299–305. doi: 10.1002/(SICI)1098-2272(1997)14:3<299::AID-GEPI7>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  34. Fallin D., Kundtz A., Town T., Gauntlett A. C., Duara R., Barker W., Crawford F., Mullan M. No association between the low density lipoprotein receptor-related protein (LRP) gene and late-onset Alzheimer's disease in a community-based sample. Neurosci Lett. 1997 Sep 19;233(2-3):145–147. doi: 10.1016/s0304-3940(97)00634-4. [DOI] [PubMed] [Google Scholar]
  35. Fallin D., Reading S., Schinka J., Hoyne J., Scibelli P., Gold M., Crawford F., Mullan M. No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. Am J Med Genet. 1997 Apr 18;74(2):192–194. doi: 10.1002/(sici)1096-8628(19970418)74:2<192::aid-ajmg15>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  36. Fillit H., Ding W. H., Buee L., Kalman J., Altstiel L., Lawlor B., Wolf-Klein G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett. 1991 Aug 19;129(2):318–320. doi: 10.1016/0304-3940(91)90490-k. [DOI] [PubMed] [Google Scholar]
  37. Forloni G., Chiesa R., Smiroldo S., Verga L., Salmona M., Tagliavini F., Angeretti N. Apoptosis mediated neurotoxicity induced by chronic application of beta amyloid fragment 25-35. Neuroreport. 1993 May;4(5):523–526. doi: 10.1097/00001756-199305000-00015. [DOI] [PubMed] [Google Scholar]
  38. Gabuzda D., Busciglio J., Chen L. B., Matsudaira P., Yankner B. A. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem. 1994 May 6;269(18):13623–13628. [PubMed] [Google Scholar]
  39. Glenner G. G., Wong C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984 May 16;120(3):885–890. doi: 10.1016/s0006-291x(84)80190-4. [DOI] [PubMed] [Google Scholar]
  40. Goate A. M. Molecular genetics of Alzheimer's disease. Geriatrics. 1997 Sep;52 (Suppl 2):S9–12. [PubMed] [Google Scholar]
  41. Goate A., Chartier-Harlin M. C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991 Feb 21;349(6311):704–706. doi: 10.1038/349704a0. [DOI] [PubMed] [Google Scholar]
  42. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 1993 Nov;16(11):460–465. doi: 10.1016/0166-2236(93)90078-z. [DOI] [PubMed] [Google Scholar]
  43. Goldgaber D., Harris H. W., Hla T., Maciag T., Donnelly R. J., Jacobsen J. S., Vitek M. P., Gajdusek D. C. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7606–7610. doi: 10.1073/pnas.86.19.7606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Griffin W. S., Stanley L. C., Ling C., White L., MacLeod V., Perrot L. J., White C. L., 3rd, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7611–7615. doi: 10.1073/pnas.86.19.7611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Guo Q., Furukawa K., Sopher B. L., Pham D. G., Xie J., Robinson N., Martin G. M., Mattson M. P. Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. Neuroreport. 1996 Dec 20;8(1):379–383. doi: 10.1097/00001756-199612200-00074. [DOI] [PubMed] [Google Scholar]
  46. Guo Q., Sopher B. L., Furukawa K., Pham D. G., Robinson N., Martin G. M., Mattson M. P. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. J Neurosci. 1997 Jun 1;17(11):4212–4222. doi: 10.1523/JNEUROSCI.17-11-04212.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Gómez-Ramos P., Bouras C., Morán M. A. Ultrastructural localization of butyrylcholinesterase on neurofibrillary degeneration sites in the brains of aged and Alzheimer's disease patients. Brain Res. 1994 Mar 21;640(1-2):17–24. doi: 10.1016/0006-8993(94)91852-x. [DOI] [PubMed] [Google Scholar]
  48. Haines J. L., Pritchard M. L., Saunders A. M., Schildkraut J. M., Growdon J. H., Gaskell P. C., Farrer L. A., Auerbach S. A., Gusella J. F., Locke P. A. No association between alpha 1-antichymotrypsin and familial Alzheimer's disease. Ann N Y Acad Sci. 1996 Dec 16;802:35–41. doi: 10.1111/j.1749-6632.1996.tb32596.x. [DOI] [PubMed] [Google Scholar]
  49. Haines J. L., Pritchard M. L., Saunders A. M., Schildkraut J. M., Growdon J. H., Gaskell P. C., Farrer L. A., Auerbach S. A., Gusella J. F., Locke P. A. No genetic effect of alpha1-antichymotrypsin in Alzheimer disease. Genomics. 1996 Apr 1;33(1):53–56. doi: 10.1006/geno.1996.0158. [DOI] [PubMed] [Google Scholar]
  50. Hardy J. A., Higgins G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992 Apr 10;256(5054):184–185. doi: 10.1126/science.1566067. [DOI] [PubMed] [Google Scholar]
  51. Hendriks L., van Duijn C. M., Cras P., Cruts M., Van Hul W., van Harskamp F., Warren A., McInnis M. G., Antonarakis S. E., Martin J. J. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet. 1992 Jun;1(3):218–221. doi: 10.1038/ng0692-218. [DOI] [PubMed] [Google Scholar]
  52. Higuchi S., Muramatsu T., Matsushita S., Arai H., Sasaki H. Presenilin-1 polymorphism and Alzheimer's disease. Lancet. 1996 Apr 27;347(9009):1186–1186. [PubMed] [Google Scholar]
  53. Hughes S. R., Khorkova O., Goyal S., Knaeblein J., Heroux J., Riedel N. G., Sahasrabudhe S. Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3275–3280. doi: 10.1073/pnas.95.6.3275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Hutchin T. P., Heath P. R., Pearson R. C., Sinclair A. J. Mitochondrial DNA mutations in Alzheimer's disease. Biochem Biophys Res Commun. 1997 Dec 18;241(2):221–225. doi: 10.1006/bbrc.1997.7793. [DOI] [PubMed] [Google Scholar]
  55. Hutchin T., Cortopassi G. A mitochondrial DNA clone is associated with increased risk for Alzheimer disease. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6892–6895. doi: 10.1073/pnas.92.15.6892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Itzhaki R. F., Lin W. R., Shang D., Wilcock G. K., Faragher B., Jamieson G. A. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet. 1997 Jan 25;349(9047):241–244. doi: 10.1016/S0140-6736(96)10149-5. [DOI] [PubMed] [Google Scholar]
  57. Jarrett J. T., Berger E. P., Lansbury P. T., Jr The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993 May 11;32(18):4693–4697. doi: 10.1021/bi00069a001. [DOI] [PubMed] [Google Scholar]
  58. Jokinen E., Sakai J., Yamamoto T., Hobbs H. H. CGG triple repeat polymorphism in VLDL receptor (VLDL-R) gene. Hum Mol Genet. 1994 Mar;3(3):521–521. doi: 10.1093/hmg/3.3.521. [DOI] [PubMed] [Google Scholar]
  59. Kamboh M. I., Sanghera D. K., Ferrell R. E., DeKosky S. T. APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. Nat Genet. 1995 Aug;10(4):486–488. doi: 10.1038/ng0895-486. [DOI] [PubMed] [Google Scholar]
  60. Kang D. E., Saitoh T., Chen X., Xia Y., Masliah E., Hansen L. A., Thomas R. G., Thal L. J., Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology. 1997 Jul;49(1):56–61. doi: 10.1212/wnl.49.1.56. [DOI] [PubMed] [Google Scholar]
  61. Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K., Müller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987 Feb 19;325(6106):733–736. doi: 10.1038/325733a0. [DOI] [PubMed] [Google Scholar]
  62. Kehoe P., Williams J., Lovestone S., Wilcock G., Owen M. J. Presenilin-1 polymorphism and Alzheimer's disease. The UK Alzheimer's Disease Collaborative Group. Lancet. 1996 Apr 27;347(9009):1185–1185. [PubMed] [Google Scholar]
  63. Kish S. J., el-Awar M., Schut L., Leach L., Oscar-Berman M., Freedman M. Cognitive deficits in olivopontocerebellar atrophy: implications for the cholinergic hypothesis of Alzheimer's dementia. Ann Neurol. 1988 Aug;24(2):200–206. doi: 10.1002/ana.410240205. [DOI] [PubMed] [Google Scholar]
  64. Koh J. Y., Yang L. L., Cotman C. W. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 1990 Nov 19;533(2):315–320. doi: 10.1016/0006-8993(90)91355-k. [DOI] [PubMed] [Google Scholar]
  65. Kordula T., Rydel R. E., Brigham E. F., Horn F., Heinrich P. C., Travis J. Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha1-antichymotrypsin expression in human cortical astrocytes. J Biol Chem. 1998 Feb 13;273(7):4112–4118. doi: 10.1074/jbc.273.7.4112. [DOI] [PubMed] [Google Scholar]
  66. Kounnas M. Z., Moir R. D., Rebeck G. W., Bush A. I., Argraves W. S., Tanzi R. E., Hyman B. T., Strickland D. K. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell. 1995 Jul 28;82(2):331–340. doi: 10.1016/0092-8674(95)90320-8. [DOI] [PubMed] [Google Scholar]
  67. Lambert J. C., Pasquier F., Cottel D., Frigard B., Amouyel P., Chartier-Harlin M. C. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum Mol Genet. 1998 Mar;7(3):533–540. doi: 10.1093/hmg/7.3.533. [DOI] [PubMed] [Google Scholar]
  68. Lambert J. C., Wavrant-De Vrièze F., Amouyel P., Chartier-Harlin M. C. Association at LRP gene locus with sporadic late-onset Alzheimer's disease. Lancet. 1998 Jun 13;351(9118):1787–1788. doi: 10.1016/s0140-6736(05)78749-3. [DOI] [PubMed] [Google Scholar]
  69. Lassmann H., Bancher C., Breitschopf H., Wegiel J., Bobinski M., Jellinger K., Wisniewski H. M. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol. 1995;89(1):35–41. doi: 10.1007/BF00294257. [DOI] [PubMed] [Google Scholar]
  70. Lee M. K., Borchelt D. R., Kim G., Thinakaran G., Slunt H. H., Ratovitski T., Martin L. J., Kittur A., Gandy S., Levey A. I. Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med. 1997 Jul;3(7):756–760. doi: 10.1038/nm0797-756. [DOI] [PubMed] [Google Scholar]
  71. Lee V. M., Balin B. J., Otvos L., Jr, Trojanowski J. Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science. 1991 Feb 8;251(4994):675–678. doi: 10.1126/science.1899488. [DOI] [PubMed] [Google Scholar]
  72. Lehmann D. J., Johnston C., Smith A. D. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet. 1997 Oct;6(11):1933–1936. doi: 10.1093/hmg/6.11.1933. [DOI] [PubMed] [Google Scholar]
  73. Lendon C. L., Talbot C. J., Craddock N. J., Han S. W., Wragg M., Morris J. C., Goate A. M. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Neurosci Lett. 1997 Feb 7;222(3):187–190. doi: 10.1016/s0304-3940(97)13381-x. [DOI] [PubMed] [Google Scholar]
  74. Levitan D., Greenwald I. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature. 1995 Sep 28;377(6547):351–354. doi: 10.1038/377351a0. [DOI] [PubMed] [Google Scholar]
  75. Levy-Lahad E., Wasco W., Poorkaj P., Romano D. M., Oshima J., Pettingell W. H., Yu C. E., Jondro P. D., Schmidt S. D., Wang K. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995 Aug 18;269(5226):973–977. doi: 10.1126/science.7638622. [DOI] [PubMed] [Google Scholar]
  76. Levy-Lahad E., Wijsman E. M., Nemens E., Anderson L., Goddard K. A., Weber J. L., Bird T. D., Schellenberg G. D. A familial Alzheimer's disease locus on chromosome 1. Science. 1995 Aug 18;269(5226):970–973. doi: 10.1126/science.7638621. [DOI] [PubMed] [Google Scholar]
  77. Levy E., Carman M. D., Fernandez-Madrid I. J., Power M. D., Lieberburg I., van Duinen S. G., Bots G. T., Luyendijk W., Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science. 1990 Jun 1;248(4959):1124–1126. doi: 10.1126/science.2111584. [DOI] [PubMed] [Google Scholar]
  78. Li Y. M., Dickson D. W. Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease. Neurosci Lett. 1997 May 2;226(3):155–158. doi: 10.1016/s0304-3940(97)00266-8. [DOI] [PubMed] [Google Scholar]
  79. Li Y. M., Steffes M., Donnelly T., Liu C., Fuh H., Basgen J., Bucala R., Vlassara H. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3902–3907. doi: 10.1073/pnas.93.9.3902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Lin F. H., Lin R., Wisniewski H. M., Hwang Y. W., Grundke-Iqbal I., Healy-Louie G., Iqbal K. Detection of point mutations in codon 331 of mitochondrial NADH dehydrogenase subunit 2 in Alzheimer's brains. Biochem Biophys Res Commun. 1992 Jan 15;182(1):238–246. doi: 10.1016/s0006-291x(05)80136-6. [DOI] [PubMed] [Google Scholar]
  81. Loo D. T., Copani A., Pike C. J., Whittemore E. R., Walencewicz A. J., Cotman C. W. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7951–7955. doi: 10.1073/pnas.90.17.7951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Lucassen P. J., Chung W. C., Kamphorst W., Swaab D. F. DNA damage distribution in the human brain as shown by in situ end labeling; area-specific differences in aging and Alzheimer disease in the absence of apoptotic morphology. J Neuropathol Exp Neurol. 1997 Aug;56(8):887–900. doi: 10.1097/00005072-199708000-00007. [DOI] [PubMed] [Google Scholar]
  83. Ma J., Yee A., Brewer H. B., Jr, Das S., Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994 Nov 3;372(6501):92–94. doi: 10.1038/372092a0. [DOI] [PubMed] [Google Scholar]
  84. Mackiewicz A., Speroff T., Ganapathi M. K., Kushner I. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol. 1991 May 1;146(9):3032–3037. [PubMed] [Google Scholar]
  85. Maestre G., Ottman R., Stern Y., Gurland B., Chun M., Tang M. X., Shelanski M., Tycko B., Mayeux R. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol. 1995 Feb;37(2):254–259. doi: 10.1002/ana.410370217. [DOI] [PubMed] [Google Scholar]
  86. Matthijs G., Marynen P. A deletion polymorphism in the human alpha-2-macroglobulin (A2M) gene. Nucleic Acids Res. 1991 Sep 25;19(18):5102–5102. doi: 10.1093/nar/19.18.5102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Mattson M. P., Guo Q., Furukawa K., Pedersen W. A. Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer's disease. J Neurochem. 1998 Jan;70(1):1–14. doi: 10.1046/j.1471-4159.1998.70010001.x. [DOI] [PubMed] [Google Scholar]
  88. Mesulam M. M., Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol. 1994 Nov;36(5):722–727. doi: 10.1002/ana.410360506. [DOI] [PubMed] [Google Scholar]
  89. Morgan K., Morgan L., Carpenter K., Lowe J., Lam L., Cave S., Xuereb J., Wischik C., Harrington C., Kalsheker N. A. Microsatellite polymorphism of the alpha 1-antichymotrypsin gene locus associated with sporadic Alzheimer's disease. Hum Genet. 1997 Jan;99(1):27–31. doi: 10.1007/s004390050304. [DOI] [PubMed] [Google Scholar]
  90. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Titani K., Ihara Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron. 1993 Jun;10(6):1151–1160. doi: 10.1016/0896-6273(93)90063-w. [DOI] [PubMed] [Google Scholar]
  91. Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992 Aug;1(5):345–347. doi: 10.1038/ng0892-345. [DOI] [PubMed] [Google Scholar]
  92. Murphy G. M., Jr, Sullivan E. V., Gallagher-Thompson D., Thompson L. W., van Duijn C. M., Forno L. S., Ellis W. G., Jagust W. J., Yesavage J., Tinklenberg J. R. No association between the alpha 1-antichymotrypsin A allele and Alzheimer's disease. Neurology. 1997 May;48(5):1313–1316. doi: 10.1212/wnl.48.5.1313. [DOI] [PubMed] [Google Scholar]
  93. Murrell J., Farlow M., Ghetti B., Benson M. D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science. 1991 Oct 4;254(5028):97–99. doi: 10.1126/science.1925564. [DOI] [PubMed] [Google Scholar]
  94. Müller-Höcker J. Cytochrome-c-oxidase deficient cardiomyocytes in the human heart--an age-related phenomenon. A histochemical ultracytochemical study. Am J Pathol. 1989 May;134(5):1167–1173. [PMC free article] [PubMed] [Google Scholar]
  95. Nacmias B., Tedde A., Latorraca S., Piacentini S., Bracco L., Amaducci L., Guarnieri B. M., Petruzzi C., Ortenzi L., Sorbi S. Apolipoprotein E and alpha1-antichymotrypsin polymorphism in Alzheimer's disease. Ann Neurol. 1996 Oct;40(4):678–680. doi: 10.1002/ana.410400420. [DOI] [PubMed] [Google Scholar]
  96. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991 Feb 8;541(1):163–166. doi: 10.1016/0006-8993(91)91092-f. [DOI] [PubMed] [Google Scholar]
  97. Nee L. E., Eldridge R., Sunderland T., Thomas C. B., Katz D., Thompson K. E., Weingartner H., Weiss H., Julian C., Cohen R. Dementia of the Alzheimer type: clinical and family study of 22 twin pairs. Neurology. 1987 Mar;37(3):359–363. doi: 10.1212/wnl.37.3.359. [DOI] [PubMed] [Google Scholar]
  98. Okuizumi K., Onodera O., Namba Y., Ikeda K., Yamamoto T., Seki K., Ueki A., Nanko S., Tanaka H., Takahashi H. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat Genet. 1995 Oct;11(2):207–209. doi: 10.1038/ng1095-207. [DOI] [PubMed] [Google Scholar]
  99. Okuizumi K., Onodera O., Seki K., Tanaka H., Namba Y., Ikeda K., Saunders A. M., Pericak-Vance M. A., Roses A. D., Tsuji S. Lack of association of very low density lipoprotein receptor gene polymorphism with Caucasian Alzheimer's disease. Ann Neurol. 1996 Aug;40(2):251–254. doi: 10.1002/ana.410400220. [DOI] [PubMed] [Google Scholar]
  100. Okuizumi K., Onodera O., Tanaka H., Kobayashi H., Tsuji S., Takahashi H., Oyanagi K., Seki K., Tanaka M., Naruse S. ApoE-epsilon 4 and early-onset Alzheimer's. Nat Genet. 1994 May;7(1):10–11. doi: 10.1038/ng0594-10b. [DOI] [PubMed] [Google Scholar]
  101. Palmer A. M., Procter A. W., Stratmann G. C., Bowen D. M. Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease. Neurosci Lett. 1986 May 15;66(2):199–204. doi: 10.1016/0304-3940(86)90190-4. [DOI] [PubMed] [Google Scholar]
  102. Pappolla M. A., Omar R. A., Kim K. S., Robakis N. K. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am J Pathol. 1992 Mar;140(3):621–628. [PMC free article] [PubMed] [Google Scholar]
  103. Paradis E., Douillard H., Koutroumanis M., Goodyer C., LeBlanc A. Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. J Neurosci. 1996 Dec 1;16(23):7533–7539. doi: 10.1523/JNEUROSCI.16-23-07533.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Parker W. D., Jr, Filley C. M., Parks J. K. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology. 1990 Aug;40(8):1302–1303. doi: 10.1212/wnl.40.8.1302. [DOI] [PubMed] [Google Scholar]
  105. Payami H., Montee K. R., Kaye J. A., Bird T. D., Yu C. E., Wijsman E. M., Schellenberg G. D. Alzheimer's disease, apolipoprotein E4, and gender. JAMA. 1994 May 4;271(17):1316–1317. [PubMed] [Google Scholar]
  106. Payami H., Zareparsi S., Montee K. R., Sexton G. J., Kaye J. A., Bird T. D., Yu C. E., Wijsman E. M., Heston L. L., Litt M. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet. 1996 Apr;58(4):803–811. [PMC free article] [PubMed] [Google Scholar]
  107. Perez-Tur J., Froelich S., Prihar G., Crook R., Baker M., Duff K., Wragg M., Busfield F., Lendon C., Clark R. F. A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene. Neuroreport. 1995 Dec 29;7(1):297–301. [PubMed] [Google Scholar]
  108. Pericak-Vance M. A., Bass M. P., Yamaoka L. H., Gaskell P. C., Scott W. K., Terwedow H. A., Menold M. M., Conneally P. M., Small G. W., Vance J. M. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA. 1997 Oct 15;278(15):1237–1241. [PubMed] [Google Scholar]
  109. Pericak-Vance M. A., Bebout J. L., Gaskell P. C., Jr, Yamaoka L. H., Hung W. Y., Alberts M. J., Walker A. P., Bartlett R. J., Haynes C. A., Welsh K. A. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet. 1991 Jun;48(6):1034–1050. [PMC free article] [PubMed] [Google Scholar]
  110. Perry E. K., Perry R. H., Blessed G., Tomlinson B. E. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 1978 Jul-Aug;4(4):273–277. doi: 10.1111/j.1365-2990.1978.tb00545.x. [DOI] [PubMed] [Google Scholar]
  111. Perry E. K., Perry R. H., Blessed G., Tomlinson B. E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet. 1977 Jan 22;1(8004):189–189. doi: 10.1016/s0140-6736(77)91780-9. [DOI] [PubMed] [Google Scholar]
  112. Petruzzella V., Chen X., Schon E. A. Is a point mutation in the mitochondrial ND2 gene associated with Alzheimer's disease. Biochem Biophys Res Commun. 1992 Jul 15;186(1):491–497. doi: 10.1016/s0006-291x(05)80834-4. [DOI] [PubMed] [Google Scholar]
  113. Pike C. J., Walencewicz A. J., Glabe C. G., Cotman C. W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 1991 Nov 1;563(1-2):311–314. doi: 10.1016/0006-8993(91)91553-d. [DOI] [PubMed] [Google Scholar]
  114. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 1993 Sep 18;342(8873):697–699. doi: 10.1016/0140-6736(93)91705-q. [DOI] [PubMed] [Google Scholar]
  115. Pritchard M. L., Saunders A. M., Gaskell P. C., Small G. W., Conneally P. M., Rosi B., Yamaoka L. H., Roses A. D., Haines J. L., Pericak-Vance M. A. No association between very low density lipoprotein receptor (VLDL-R) and Alzheimer disease in American Caucasians. Neurosci Lett. 1996 May 10;209(2):105–108. doi: 10.1016/0304-3940(96)12630-6. [DOI] [PubMed] [Google Scholar]
  116. Pérez-Tur J., Wavrant-De Vrieze F., Lambert J. C., Chartier-Harlin M. C. Presenilin-1 polymorphism and Alzheimer's disease. The Alzheimer's Study Group. Lancet. 1996 Jun 1;347(9014):1560–1561. [PubMed] [Google Scholar]
  117. Raiha I., Kaprio J., Koskenvuo M., Rajala T., Sourander L. Alzheimer's disease in Finnish twins. Lancet. 1996 Mar 2;347(9001):573–578. doi: 10.1016/s0140-6736(96)91272-6. [DOI] [PubMed] [Google Scholar]
  118. Rebeck G. W., Harr S. D., Strickland D. K., Hyman B. T. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol. 1995 Feb;37(2):211–217. doi: 10.1002/ana.410370212. [DOI] [PubMed] [Google Scholar]
  119. Rocca W. A., Hofman A., Brayne C., Breteler M. M., Clarke M., Copeland J. R., Dartigues J. F., Engedal K., Hagnell O., Heeren T. J. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol. 1991 Sep;30(3):381–390. doi: 10.1002/ana.410300310. [DOI] [PubMed] [Google Scholar]
  120. Rozemuller J. M., Abbink J. J., Kamp A. M., Stam F. C., Hack C. E., Eikelenboom P. Distribution pattern and functional state of alpha 1-antichymotrypsin in plaques and vascular amyloid in Alzheimer's disease. A immunohistochemical study with monoclonal antibodies against native and inactivated alpha 1-antichymotrypsin. Acta Neuropathol. 1991;82(3):200–207. doi: 10.1007/BF00294446. [DOI] [PubMed] [Google Scholar]
  121. Sakai J., Hoshino A., Takahashi S., Miura Y., Ishii H., Suzuki H., Kawarabayasi Y., Yamamoto T. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J Biol Chem. 1994 Jan 21;269(3):2173–2182. [PubMed] [Google Scholar]
  122. Saunders A. M., Strittmatter W. J., Schmechel D., George-Hyslop P. H., Pericak-Vance M. A., Joo S. H., Rosi B. L., Gusella J. F., Crapper-MacLachlan D. R., Alberts M. J. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993 Aug;43(8):1467–1472. doi: 10.1212/wnl.43.8.1467. [DOI] [PubMed] [Google Scholar]
  123. Schellenberg G. D., Bird T. D., Wijsman E. M., Orr H. T., Anderson L., Nemens E., White J. A., Bonnycastle L., Weber J. L., Alonso M. E. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science. 1992 Oct 23;258(5082):668–671. doi: 10.1126/science.1411576. [DOI] [PubMed] [Google Scholar]
  124. Schellenberg G. D., Boehnke M., Wijsman E. M., Moore D. K., Martin G. M., Bird T. D. Genetic association and linkage analysis of the apolipoprotein CII locus and familial Alzheimer's disease. Ann Neurol. 1992 Feb;31(2):223–227. doi: 10.1002/ana.410310214. [DOI] [PubMed] [Google Scholar]
  125. Schellenberg G. D., Deeb S. S., Boehnke M., Bryant E. M., Martin G. M., Lampe T. H., Bird T. D. Association of an apolipoprotein CII allele with familial dementia of the Alzheimer type. J Neurogenet. 1987 Apr;4(2-3):97–108. [PubMed] [Google Scholar]
  126. Schellenberg G. D., Payami H., Wijsman E. M., Orr H. T., Goddard K. A., Anderson L., Nemens E., White J. A., Alonso M. E., Ball M. J. Chromosome 14 and late-onset familial Alzheimer disease (FAD). Am J Hum Genet. 1993 Sep;53(3):619–628. [PMC free article] [PubMed] [Google Scholar]
  127. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T. D., Hardy J., Hutton M., Kukull W. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996 Aug;2(8):864–870. doi: 10.1038/nm0896-864. [DOI] [PubMed] [Google Scholar]
  128. Scott W. K., Roses A. D., Haines J. L., Pericak-Vance M. A. Presenilin-1 polymorphism and Alzheimer's disease. Lancet. 1996 Jun 1;347(9014):1560–1560. [PubMed] [Google Scholar]
  129. Shen J., Bronson R. T., Chen D. F., Xia W., Selkoe D. J., Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997 May 16;89(4):629–639. doi: 10.1016/s0092-8674(00)80244-5. [DOI] [PubMed] [Google Scholar]
  130. Shoffner J. M., Brown M. D., Torroni A., Lott M. T., Cabell M. F., Mirra S. S., Beal M. F., Yang C. C., Gearing M., Salvo R. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics. 1993 Jul;17(1):171–184. doi: 10.1006/geno.1993.1299. [DOI] [PubMed] [Google Scholar]
  131. Shoji M., Hirai S., Yamaguchi H., Harigaya Y., Ishiguro K., Matsubara E. Alpha 1-antichymotrypsin is present in diffuse senile plaques. A comparative study of beta-protein and alpha 1-antichymotrypsin immunostaining in the Alzheimer brain. Am J Pathol. 1991 Jan;138(1):247–257. [PMC free article] [PubMed] [Google Scholar]
  132. Sims N. R., Finegan J. M., Blass J. P. Altered metabolic properties of cultured skin fibroblasts in Alzheimer's disease. Ann Neurol. 1987 May;21(5):451–457. doi: 10.1002/ana.410210507. [DOI] [PubMed] [Google Scholar]
  133. Singleton A. B., Smith G., Gibson A. M., Woodward R., Perry R. H., Ince P. G., Edwardson J. A., Morris C. M. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. Hum Mol Genet. 1998 May;7(5):937–939. doi: 10.1093/hmg/7.5.937. [DOI] [PubMed] [Google Scholar]
  134. Smale G., Nichols N. R., Brady D. R., Finch C. E., Horton W. E., Jr Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol. 1995 Jun;133(2):225–230. doi: 10.1006/exnr.1995.1025. [DOI] [PubMed] [Google Scholar]
  135. Smith M. A., Kutty R. K., Richey P. L., Yan S. D., Stern D., Chader G. J., Wiggert B., Petersen R. B., Perry G. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol. 1994 Jul;145(1):42–47. [PMC free article] [PubMed] [Google Scholar]
  136. Song Y. Q., Rogaeva E., Premkumar S., Brindle N., Kawarai T., Orlacchio A., Yu G., Levesque G., Nishimura M., Ikeda M. Absence of association between Alzheimer disease and the -491 regulatory region polymorphism of APOE. Neurosci Lett. 1998 Jul 10;250(3):189–192. doi: 10.1016/s0304-3940(98)00470-4. [DOI] [PubMed] [Google Scholar]
  137. Sorbi S., Nacmias B., Forleo P., Latorraca S., Gobbini I., Bracco L., Piacentini S., Amaducci L. ApoE allele frequencies in Italian sporadic and familial Alzheimer's disease. Neurosci Lett. 1994 Aug 15;177(1-2):100–102. doi: 10.1016/0304-3940(94)90054-x. [DOI] [PubMed] [Google Scholar]
  138. St George-Hyslop P., Haines J., Rogaev E., Mortilla M., Vaula G., Pericak-Vance M., Foncin J. F., Montesi M., Bruni A., Sorbi S. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet. 1992 Dec;2(4):330–334. doi: 10.1038/ng1292-330. [DOI] [PubMed] [Google Scholar]
  139. Stadelmann C., Brück W., Bancher C., Jellinger K., Lassmann H. Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathol Exp Neurol. 1998 May;57(5):456–464. doi: 10.1097/00005072-199805000-00009. [DOI] [PubMed] [Google Scholar]
  140. Su J. H., Deng G., Cotman C. W. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol. 1997 Jan;56(1):86–93. doi: 10.1097/00005072-199701000-00009. [DOI] [PubMed] [Google Scholar]
  141. Takahashi S., Kawarabayasi Y., Nakai T., Sakai J., Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9252–9256. doi: 10.1073/pnas.89.19.9252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Talbot C., Houlden H., Craddock N., Crook R., Hutton M., Lendon C., Prihar G., Morris J. C., Hardy J., Goate A. Polymorphism in AACT gene may lower age of onset of Alzheimer's disease. Neuroreport. 1996 Jan 31;7(2):534–536. doi: 10.1097/00001756-199601310-00038. [DOI] [PubMed] [Google Scholar]
  143. Tanzi R. E., Gusella J. F., Watkins P. C., Bruns G. A., St George-Hyslop P., Van Keuren M. L., Patterson D., Pagan S., Kurnit D. M., Neve R. L. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 1987 Feb 20;235(4791):880–884. doi: 10.1126/science.2949367. [DOI] [PubMed] [Google Scholar]
  144. Terry R. D. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol. 1996 Oct;55(10):1023–1025. [PubMed] [Google Scholar]
  145. Thome J., Baumer A., Kornhuber J., Rösler M., Riederer P. Alpha-1-antichymotrypsin bi-allele polymorphism, apolipoprotein-E tri-allele polymorphism and genetic risk of Alzheimer's syndrome. J Neural Transm Park Dis Dement Sect. 1995;10(2-3):207–212. doi: 10.1007/BF02251232. [DOI] [PubMed] [Google Scholar]
  146. Trounce I., Byrne E., Marzuki S. Decline in skeletal muscle mitochondrial respiratory chain function: possible factor in ageing. Lancet. 1989 Mar 25;1(8639):637–639. doi: 10.1016/s0140-6736(89)92143-0. [DOI] [PubMed] [Google Scholar]
  147. Tsai M. S., Tangalos E. G., Petersen R. C., Smith G. E., Schaid D. J., Kokmen E., Ivnik R. J., Thibodeau S. N. Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet. 1994 Apr;54(4):643–649. [PMC free article] [PubMed] [Google Scholar]
  148. Tysoe C., Galinsky D., Robinson D., Brayne C. E., Easton D. F., Huppert F. A., Dening T., Paykel E. S., Rubinsztein D. C. Analysis of alpha-1 antichymotrypsin, presenilin-1, angiotensin-converting enzyme, and methylenetetrahydrofolate reductase loci as candidates for dementia. Am J Med Genet. 1997 Apr 18;74(2):207–212. doi: 10.1002/(sici)1096-8628(19970418)74:2<207::aid-ajmg20>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  149. Tysoe C., Robinson D., Brayne C., Dening T., Paykel E. S., Huppert F. A., Rubinsztein D. C. The tRNA(Gln) 4336 mitochondrial DNA variant is not a high penetrance mutation which predisposes to dementia before the age of 75 years. J Med Genet. 1996 Dec;33(12):1002–1006. doi: 10.1136/jmg.33.12.1002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Tysoe C., Whittaker J., Cairns N. J., Atkinson P. F., Harrington C. R., Xuereb J., Wilcock G., Rubinsztein D. C. Presenilin-1 intron 8 polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease. Neurosci Lett. 1997 Jan 24;222(1):68–69. doi: 10.1016/s0304-3940(97)13339-0. [DOI] [PubMed] [Google Scholar]
  151. Van Broeckhoven C., Backhovens H., Cruts M., De Winter G., Bruyland M., Cras P., Martin J. J. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. Nat Genet. 1992 Dec;2(4):335–339. doi: 10.1038/ng1292-335. [DOI] [PubMed] [Google Scholar]
  152. Van Broeckhoven C. Presenilins and Alzheimer disease. Nat Genet. 1995 Nov;11(3):230–232. doi: 10.1038/ng1195-230. [DOI] [PubMed] [Google Scholar]
  153. Vitek M. P., Bhattacharya K., Glendening J. M., Stopa E., Vlassara H., Bucala R., Manogue K., Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4766–4770. doi: 10.1073/pnas.91.11.4766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  154. Vlassara H. Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med. 1994 Jul;124(1):19–30. [PubMed] [Google Scholar]
  155. Walsh J. S., Welch H. G., Larson E. B. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med. 1990 Sep 15;113(6):429–434. doi: 10.7326/0003-4819-113-6-429. [DOI] [PubMed] [Google Scholar]
  156. Wavrant-DeVrièze F., Pérez-Tur J., Lambert J. C., Frigard B., Pasquier F., Delacourte A., Amouyel P., Hardy J., Chartier-Harlin M. C. Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. Neurosci Lett. 1997 May 9;227(1):68–70. doi: 10.1016/s0304-3940(97)00304-2. [DOI] [PubMed] [Google Scholar]
  157. Whitson J. S., Glabe C. G., Shintani E., Abcar A., Cotman C. W. Beta-amyloid protein promotes neuritic branching in hippocampal cultures. Neurosci Lett. 1990 Mar 14;110(3):319–324. doi: 10.1016/0304-3940(90)90867-9. [DOI] [PubMed] [Google Scholar]
  158. Whitson J. S., Mims M. P., Strittmatter W. J., Yamaki T., Morrisett J. D., Appel S. H. Attenuation of the neurotoxic effect of A beta amyloid peptide by apolipoprotein E. Biochem Biophys Res Commun. 1994 Feb 28;199(1):163–170. doi: 10.1006/bbrc.1994.1209. [DOI] [PubMed] [Google Scholar]
  159. Whitson J. S., Selkoe D. J., Cotman C. W. Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science. 1989 Mar 17;243(4897):1488–1490. doi: 10.1126/science.2928783. [DOI] [PubMed] [Google Scholar]
  160. Wolozin B. L., Pruchnicki A., Dickson D. W., Davies P. A neuronal antigen in the brains of Alzheimer patients. Science. 1986 May 2;232(4750):648–650. doi: 10.1126/science.3083509. [DOI] [PubMed] [Google Scholar]
  161. Wolozin B., Iwasaki K., Vito P., Ganjei J. K., Lacanà E., Sunderland T., Zhao B., Kusiak J. W., Wasco W., D'Adamio L. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science. 1996 Dec 6;274(5293):1710–1713. doi: 10.1126/science.274.5293.1710. [DOI] [PubMed] [Google Scholar]
  162. Wong P. C., Zheng H., Chen H., Becher M. W., Sirinathsinghji D. J., Trumbauer M. E., Chen H. Y., Price D. L., Van der Ploeg L. H., Sisodia S. S. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature. 1997 May 15;387(6630):288–292. doi: 10.1038/387288a0. [DOI] [PubMed] [Google Scholar]
  163. Wragg M. A., Talbot C. J., Morris J. C., Lendon C. L., Goate A. M. No association found between Alzheimer's disease and a mitochondrial tRNA glutamine gene variant. Neurosci Lett. 1995 Dec 8;201(2):107–110. doi: 10.1016/0304-3940(95)12146-3. [DOI] [PubMed] [Google Scholar]
  164. Wragg M., Hutton M., Talbot C. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group. Lancet. 1996 Feb 24;347(9000):509–512. doi: 10.1016/s0140-6736(96)91140-x. [DOI] [PubMed] [Google Scholar]
  165. Yamamoto M., Kondo I., Ogawa N., Asanuma M., Yamashita Y., Mizuno Y. Genetic association between susceptibility to Parkinson's disease and alpha1-antichymotrypsin polymorphism. Brain Res. 1997 Jun 6;759(1):153–155. doi: 10.1016/s0006-8993(97)00330-2. [DOI] [PubMed] [Google Scholar]
  166. Yamatsuji T., Okamoto T., Takeda S., Murayama Y., Tanaka N., Nishimoto I. Expression of V642 APP mutant causes cellular apoptosis as Alzheimer trait-linked phenotype. EMBO J. 1996 Feb 1;15(3):498–509. [PMC free article] [PubMed] [Google Scholar]
  167. Yankner B. A., Dawes L. R., Fisher S., Villa-Komaroff L., Oster-Granite M. L., Neve R. L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 1989 Jul 28;245(4916):417–420. doi: 10.1126/science.2474201. [DOI] [PubMed] [Google Scholar]
  168. Yankner B. A., Duffy L. K., Kirschner D. A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990 Oct 12;250(4978):279–282. doi: 10.1126/science.2218531. [DOI] [PubMed] [Google Scholar]
  169. Yen T. C., Chen Y. S., King K. L., Yeh S. H., Wei Y. H. Liver mitochondrial respiratory functions decline with age. Biochem Biophys Res Commun. 1989 Dec 29;165(3):944–1003. doi: 10.1016/0006-291x(89)92701-0. [DOI] [PubMed] [Google Scholar]
  170. Yoshiiwa A., Kamino K., Yamamoto H., Kobayashi T., Imagawa M., Nonomura Y., Yoneda H., Sakai T., Nishiwaki Y., Sato N. alpha 1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E epsilon 4 allele carriers. Ann Neurol. 1997 Jul;42(1):115–117. doi: 10.1002/ana.410420118. [DOI] [PubMed] [Google Scholar]
  171. Zubenko G. S., Stiffler J. S., Hughes H. B., Hurtt M. R., Kaplan B. B. Initial results of a genome survey for novel Alzheimer's disease risk genes: association with a locus on the X chromosome. Am J Med Genet. 1998 Feb 7;81(1):98–107. doi: 10.1002/(sici)1096-8628(19980207)81:1<98::aid-ajmg17>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  172. van Duijn C. M., Stijnen T., Hofman A. Risk factors for Alzheimer's disease: overview of the EURODEM collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20 (Suppl 2):S4–12. doi: 10.1093/ije/20.supplement_2.s4. [DOI] [PubMed] [Google Scholar]
  173. van Leeuwen F. W., de Kleijn D. P., van den Hurk H. H., Neubauer A., Sonnemans M. A., Sluijs J. A., Köycü S., Ramdjielal R. D., Salehi A., Martens G. J. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science. 1998 Jan 9;279(5348):242–247. doi: 10.1126/science.279.5348.242. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES